J2KBIO Q1 2026: Revenue +53%, Net Profit +568% YoY, Cash Dividend
-
Consolidated revenue: 11.1 billion KRW (+53% YoY), operating profit: 1.9 billion KRW (+58% YoY)
-
Consolidated net profit: 1.6 billion KRW (+568% YoY), EPS 273 KRW
-
Cash dividend for FY2025: 1.46 billion KRW (~250 KRW per share)
-
Debt ratio 21.1%, cash and equivalents 8.9 billion KRW
-
Credit rating BBB0 (NICE), no contingencies or litigation
-
R&D expenses 0.62 billion KRW (5.6% of revenue)
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: J2KBIO (420570)
-
Submission: J2KBIO Co., Ltd.
-
Receipt: 05-14-2026